+

WO2016066668A1 - Pharmaceutical combinations of vildagliptin and ppar agonists - Google Patents

Pharmaceutical combinations of vildagliptin and ppar agonists Download PDF

Info

Publication number
WO2016066668A1
WO2016066668A1 PCT/EP2015/074939 EP2015074939W WO2016066668A1 WO 2016066668 A1 WO2016066668 A1 WO 2016066668A1 EP 2015074939 W EP2015074939 W EP 2015074939W WO 2016066668 A1 WO2016066668 A1 WO 2016066668A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical combination
vildagliptin
tablets
combination according
weight
Prior art date
Application number
PCT/EP2015/074939
Other languages
French (fr)
Inventor
Ali TÜRKYILMAZ
Ayse ILDES ERDEM
Gülay Yelken
Mehtap Saydam
Onur Ülgen
Original Assignee
Sanovel Ilac Sanayi Ve Ticaret A.S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi Ve Ticaret A.S. filed Critical Sanovel Ilac Sanayi Ve Ticaret A.S.
Priority to EP15797264.7A priority Critical patent/EP3212185A1/en
Publication of WO2016066668A1 publication Critical patent/WO2016066668A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • the present invention relates to a pharmaceutical combination comprising vildagliptin or a pharmaceutically acceptable salt thereof in combination with a PPAR dual agonist or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient.
  • Vildagliptin is a DPP-IV inhibitor used for type 2 or non-insulin dependent diabetes. It increases the amount of insulin produced by the body. It also decreases the amount of glucagon which is produced by the body. Because of these effects, vildagliptin can help to control blood sugar levels in people with diabetes.
  • DPP-IV inhibitors work by blocking the action of DPP-IV, an enzyme which destroys the hormone incretin.
  • DPP-IV an enzyme which destroys the hormone incretin.
  • incretin hormones There are two types of incretin hormones found in the body, called glucagon-like peptide-1 (GLP-1 ) and glucose-dependent insulinotropic peptide (GIP). These hormones are naturally produced by the body in response to food intake. Their function is to help the body produce more insulin only when it is needed and reduce the amount of glucose being produced by the liver when it is not needed.
  • Vildagliptin works by binding to DPP-IV and preventing it from breaking down the GLP-1 and GIP. This increases the levels of these hormones in the body and so increases their effect on controlling blood sugar.
  • Vdagliptin is marketed under the trademark Galvus ® in 50 mg dosage forms by NOVARTIS. It is used against diabetes mellitus, particularly in treating type 2 diabetes.
  • Galvus ® includes lactose anhydrose, microcrystalline cellulose, sodium starch glycolate and magnesium stearate.
  • Tablets comprising combinations of vildagliptin are also available in the market in the strength of 50mg/850mg and 50mg/1000mg (vildagliptin/metformin).
  • Eucreas® (vildagliptin and metformin combination) is a dipeptidyl peptidase-4 (DPP-4) inhibitor and biguanide combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
  • DPP-4 dipeptidyl peptidase-4
  • biguanide combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
  • vildagliptin and PPAR dual agonists in prior art or in the market for the treatment of cardiovascular disease in patients with type-2 diabetes mellitus.
  • PPAR agonists are drugs which act upon the peroxisome proliferator-activated receptor.
  • PPAR peroxisome proliferator-activated receptor
  • PPAR peroxisome proliferator-activated receptor
  • PPARa alpha
  • PPARy gamma
  • PPAR5 delta
  • dual acting PPARa/ ⁇ alpha/gamma
  • PPAR pan alpha/delta/gamma
  • PPAR alpha agonists are used for dyslipidemia to increase HDL (High Density Lipoprotein), decrease TG (Triglycerides) without effect on LDL (Low Density Lipoprotein).
  • PPAR gamma agonists are insulin sensitizers for type 2 diabetes.
  • PPAR delta agonists are developed to deal with glucose resulting in insulin resistance and diabetes.
  • PPAR pan (alpha/delta/gamma) agonists are for combined treatment of type 2 diabetes and dyslipidemia.
  • PPAR dual (alpha and gamma) agonists are for combined treatment of type 2 diabetes and dyslipidemia.
  • PPAR alpha agonists are also known as glitazones or thiazolidinediones (TZDs). They comprise pioglitazone, rosiglitazone, ciglitazone, darglitazone, englitazone, lobeglitazone, mitaglitazone, netoglitazone and troglitazone.
  • PPAR gamma agonists (also known as fibrates) comprise bezafibrate, ciprofibrate, clofibrate, gemfibrozil, fenofibrate, simfibrate, lifibrate, pirifibrate, theofibrate, tiafibrate, timofibrate, tocofibrate.
  • PPAR delta agonists comprise endurobol.
  • PPAR dual (alpha and gamma) agonists comprise saroglitazar, aloglitazar, chiglitazar, farglitazar (faraglitazar), imiglitazar, muraglitazar, naveglitazar, ragaglitazar, reglitazar, peliglitazar, pemoglitazar, sodelglitazar, tesaglitazar, oxeglitazar, and sipoglitazar.
  • PPAR dual agonists are the glitazars that combine increased insulin sensitization with lipid control. They bind and activate both the alpha and gamma PPAR isoforms and improvement is achieved both in lipid profiles and insulin sensitization while avoiding dyslipidemia and weight gain.
  • PPAR dual agonists are ideally suitable drugs in treatment of type 2 diabetic patients who have cardiovascular risk secondary to elevated triglyceride concentration. These molecules do not only target the dyslipidemia but also contribute to improved glycemic control.
  • Vildagliptin increases plasma GLP-1 concentration and elevate cellular cAMP levels in pancreatic beta-cells leading to potentiate insulin secretion, whereas PPAR agonists dual regulate lipid homeostasis, cellular differentiation, proliferation and the immune response. Therefore, it is anticipated that a combination therapy of vildagliptin and PPAR dual agonists may synergistically represents a novel approach to modify metabolic risk factors associated with adverse cardiovascular outcomes in patients with type 2 diabetes.
  • Lipaglyn is marketed under the trade name Lipaglyn recommended in strength of 4 mg, developed by the Zydus Cadila. Lipaglyn has been approved for the treatment of Type II diabetes by the Drug Controller General of India in 2013. Lipaglyn is indicated for the treatment of diabetic dyslipidemia and hypertriglyceridemia with Type 2 diabetes mellitus not controlled by statin therapy. In clinical studies, Lipaglyn has demonstrated reduction of triglycerides (TG), low density lipoprotein (LDL) cholesterol, very low density lipoprotein (VLDL) cholesterol, non - high density lipoprotein (non- HDL) cholesterol and an increase in HDL cholesterol.
  • TG triglycerides
  • LDL low density lipoprotein
  • VLDL very low density lipoprotein
  • non- HDL non - high density lipoprotein
  • saroglitazar (2S)-2-ethoxy-3-[4-[2-[2-methyl-5-(4-methylsulfanylphenyl)pyrrol-1 -yl]ethoxy]phenyl] propanoic acid and the chemical structure is shown in Formula II.
  • Ragaglitazar is a dual peroxisome proliferator-activated receptor (PPAR) alpha and gamma agonist intended to restore insulin sensitivity and ameliorate diabetic dyslipidemia. It is first disclosed in the patent numbered W09919313 in 1997.
  • the chemical name of Ragaglitazar is (2S)-2-ethoxy-3-[4-(2-phenoxazin-10-ylethoxy)phenyl]propanoic acid and the chemical structure is shown in Formula III.
  • Reglitazar is a PPAR dual agonist which is first disclosed in the patent numbered W09518125 in 1993.
  • the chemical name of Reglitazar is 4-[[4-[2-(5-methyl-2-phenyl-1 ,3- oxazol-4-yl)ethoxy]phenyl]methyl]-1 ,2-oxazolidine-3,5-dione and the chemical structure is shown in Formula IV.
  • a pharmaceutical combination comprising vildagliptin or a pharmaceutically acceptable salt thereof in combination with a PPAR dual agonist or a pharmaceutically acceptable salt thereof has been developed to achieve a stable pharmaceutical combination therapy with a safe and effective release.
  • the main embodiment of this present invention is to provide a pharmaceutical combination comprising vildagliptin or a pharmaceutically acceptable salt thereof in combination with a PPAR dual agonist or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient.
  • PPAR peroxisome proliferator-activated receptor
  • vildagliptin is present in an amount of between 1 .5 - 90%, preferably 15 - 50% and more preferably 25 - 35% by weight of total formulation.
  • a PPAR dual agonist is present in an amount of between 0.5 - 90.0 %, preferably 1 .0 - 50.0 % and more preferably 10.0 - 45.0 % by weight of total formulation.
  • the PPAR dual agonist is preferably saroglitazar or reglitazar or ragaglitazar their acceptable salts thereof.
  • saroglitazar or a pharmaceutically acceptable salt used in the formulation is saroglitazar magnesium salt.
  • the pharmaceutical combination of this present invention comprises vildagliptin and saroglitazar or a pharmaceutically acceptable salt thereof.
  • the pharmaceutical combination of this present invention comprises vildagliptin and reglitazar or a pharmaceutically acceptable salt thereof.
  • the pharmaceutical combination of this present invention comprises vildagliptin and ragaglitazar or a pharmaceutically acceptable salt thereof.
  • vildagliptin present in an amount of between 25 mg and 200 mg and the saroglitazar is present in an amount of 0.1 mg and 5 mg. According to this embodiment, vildagliptin present in an amount of between 25 mg and 200 mg and the reglitazar is present in an amount of 0.5 mg and 100 mg.
  • vildagliptin present in an amount of between 25mg and 200 mg and the ragaglitazar is present in an amount of 0.5 and 100 mg.
  • the pharmaceutical combination is in the form of tablets (comprising compressed, coated or uncoated), bilayer tablets, multilayer tablets, orally disintegrating tablets, mini tablets, capsules, pellet, sugar pellet, buccal tablets, sublingual tablets, effervescent compositions, effervescent tablets, immediate release tablets, modified release tablets, film-coated tablets, gastric disintegrating tablets, pills, hard or soft gelatin capsules, oral granules, powders, coated bead systems, granules, microspheres, tablet in tablet or inlay tablets, ion exchange resin systems, sterile solutions or suspensions, steril ocular solutions, aerosols, sprays, drops, ampoules, suppositories, ocular systems, parenteral systems, creams, gels, ointments, dragees, sachets; films, orally administrable films, solutions, solids; elixirs, tinctures, suspensions, syrups, colloidal dispersions, dispersions
  • pharmaceutical combination is formulated preferably in the form of tablet or capsule or bilayer tablet comprising vildagliptin or a pharmaceutically acceptable salt and PPAR dual agonist or a pharmaceutically acceptable salt.
  • One embodiment of the present invention is to obtain a stable pharmaceutical combination comprising vildagliptin or a pharmaceutically acceptable salt and a PPAR dual agonist or a pharmaceutically acceptable salt in one dosage form.
  • vildagliptin Stability related problems do occur in many active agents, including vildagliptin, under the influence of ambient and physical conditions.
  • Vildagliptin is an active agent that is highly-susceptible to air and humidity. When vildagliptin is exposed to air and humidity, it degrades structurally and develops chemical behavioral changes that may cause undesired release profile or even additional side effects.
  • a pharmaceutical combination comprising vildagliptin or a pharmaceutically acceptable salt and a PPAR dual agonist or a pharmaceutically acceptable salt which provides the desired release profile.
  • pharmaceutical combination of this present invention comprise at least one pharmaceutical excipient selected from the group comprising diluents, disintegrants, binders, glidants, lubricants, super-disintegrants, acidifying agents, alkalizing agents, sweeteners, aromas or mixtures thereof.
  • Suitable diluents are selected from the group comprising dibasic calcium phosphate, mannitol, lactose, microcrystalline cellulose (MCC), spray-dried lactose, sorbitol, sucrose, trehalose, isomalt, starch, calcium phosphate anhydrate, calcium phosphate dihydrate, calcium phosphate trihydrate, tribasic calcium phosphate, calcium carbonate, calcium sulfate, carboxymethyl cellulose calcium, powdered cellulose, cellulose acetate, pregelatinized starch, sodium carbonate, sodium bicarbonate, isomalt, maltodextrine, dextrose, calcium carbonate, sugars, magnesium carbonate, corn starch or mixtures thereof.
  • MCC microcrystalline cellulose
  • dibasic calcium phosphate is used as a diluent.
  • dibasic calcium phosphate is used in an amount of % 5.0 - 90.0 by the weight of total formulation.
  • Suitable disintegrants are selected from the group comprising crospovidon (cross-linked polyvinylpyrrolidone), copovidon, polyvinylpyrrolidone (povidone), croscarmellose sodium, polycarbophil, low-substitue HPC (hydroxylpropyl cellulose), poloxamer, sodium starch glycolate, microcristalline cellulose, starch, alginic acid and alginates, ion-exchange resins, magnesium aluminum silica, sodium dodecyl sulphate, sodium carboxy methyl cellulose, carboxy methyl cellulose calcium, docusate sodium, guar gum, polyacrylin potasium, sodium alginate, sodium glysin carbonate, sodium lauryl sulphate or mixtures thereof.
  • Suitable binders are selected from the group comprising crospovidon (cross-linked polyvinylpyrrolidone), polyvinylpyrrolidone (povidone), pullulan, polymethacrylate, glyceryl behenate, hydroxypropyl methyl cellulose (HPMC), hydroxypropyl cellulose (HPC), carboxymethyl cellulose (CMC), methyl cellulose (MC), hydroxyethyl cellulose, sodium carboxymethyl cellulose (Na CMC), carboxymethyl cellulose calcium, ethyl cellulose and other cellulose derivatives, polymetacrylates, polyethylene oxide, polyvinyl alcohol, polycarbophil, polyvinyl acetate and their copolymers, gelatin, starch, xanthan gum, guar gum, alginate, carrageen, kollagen, agar, pectin, hyaluronic acid, carbomer, cellulose acetate phthalate, hydroxypropyl starch, hydroxyethyl
  • Suitable glidants are selected from the group comprising colloidal silicon dioxide, talc, aluminum silicate, powdered cellulose, calcium phosphate tribasic, hydrophobic colloidal silica, magnesium oxide, magnesium trisilicate, magnesium silicate or mixtures thereof.
  • Suitable lubricants are selected from the group comprising magnesium stearate, calcium stearate, mineral oil, sodium stearyl fumarate, talc, polyethylene glycol, glyceryl monostearate, glyceryl palmitostearate, sodium lauryl sulphate, magnesium lauryl sulphate, fumaric acid, zinc stearate, stearic acid, hydrogenated natural oils, silica, paraffin or mixtures thereof.
  • Super-disintegrant is selected from the group comprising calcium silicate, sodium starch glycolate, croscarmellose sodium, carboxymethyl cellulose calcium, sodium carboxymethyl starch, sodium glycine carbonate, sodium lauryl sulphate, soy polysaccharide, alginic acids and algynates, cross-linked alginic acid, polyacrylin potasium, poloxamer.
  • crospovidone gellan gum, guar gum, xanthan gum, docusate sodium, magnesium alumina, sodium dodecyl sulfate, ion exchange resins or mixtures thereof.
  • Acidifying agent is selected from the group comprising fumaric acid, tartaric acid, citric acid monohydrate, citric acid anhydrate, adipic acid, ascorbic acid, acetic acid, hydrochloric acid nitric acid, phosphoric acid, nicotinic acid, acetyl salicylic acid, sulfuric acid, acid salts (such as amino acid hydrochlorides, sodium citrates, sodium citrate dihydrate, disodium citrate, disodium dihydrogen citrate, sodium acid phosphate) or mixtures thereof.
  • Alkalizing agent is selected from the group comprising sodium glycine carbonate, ammonia solution, ammonium carbonate, diethanolamine, diisopropanolamine, potassium hydroxide, potassium bicarbonate, potassium carbonate, calcium carbonate, sodium bicarbonate, sodium borate, sodium carbonate, sodium hydroxide, trolamine or mixtures thereof.
  • Suitable sweeteners may include but not limited to thaumatin, mogroside, inuline, erythritol, mogroside, acesulfame-K, aspartame, saccharin or its sodium and calcium salts, sodium cyclamate, sucrose, fructose, glucose, sorbitol or mixtures thereof.
  • Suitable aromas may include but not limited to fruit aromas such as orange, banana, strawberry, cherry, wild cherry, lemon, etc., and other aromas such as cardamom, anis, mint, menthol, vanillin or the mixtures thereof.
  • Coating may also preferably be used for the protection from the moisture. It can be selected from the group comprising polyvinyl alcohol-polyethylene glycol copolymers (Kollicoat IR), polyvinyl alcohol or copolymers or mixtures thereof (Opadry AMB), polymethylmetacrylate derivatives, Ethylcellulose Dispersions (Surelease), Kerry-HPC, polyethylene glycol, polyvinylprolidone, polyvinylprolidone-vinyl acetate copolymer (PVP-VA) and all kinds of OpadryTM, as well as pigments, dyes, titanium dioxide, iron oxide, talc or polymethylmetacrylate copolymers (Eudragit).
  • these formulations have been designed, comprising the following: tablet:
  • coating bilayer tablet h. preferably, coating bilayer tablet:
  • Example 1 tablet ingredients Amount (%) vildagliptin 1 .5 - 90.0 saroglitazar 0.5 - 90.0 polycarbophil 0.5-30.0
  • the production of the formulation is carried out as follows: vildagliptin, saroglitazar, polycarbophil, croscarmellose sodium and dibasic calcium phosphate are mixed. Colloidal silicon dioxide is added and mixed. Then, magnesium stearate is added therein and mixed for a short time. Tablet compression is performed and tablets are preferably coated.
  • Example 2 bilaver tablet ingredients Amount (%)
  • First layer vildagliptin, dibasic calcium phosphate, crospovidon and colloidal silicon dioxide are mixed. Then, magnesium stearate is added and mixed again. The mixture is passed through the roller compactor.
  • Second layer saroglitazar, dibasic calcium phosphate, crospovidon, microcrystalline cellulose and colloidal silicon dioxide are mixed. Then, magnesium stearate is added and mixed for a short time. The mixture is passed through the roller compactor.
  • Granules are sieved and mixed with magnesium stearate. Then, they compressed into bilayer tablets. Tablets are preferably coated.
  • Example 3 bilaver tablet - hot melt process
  • the production of the formulation is carried out as follows: vildagliptin, dibasic calcium phosphate, crospovidon and microcrystalline cellulose are mixed. Reglitazar and poloxamer are mixed and passed through the extruder, cooled and sieved. Both phases are mixed with first colloidal silicon dioxide and then magnesium stearate for a short time. Tablet compression is performed. Tablets are preferably coated.
  • vildagliptin and ragaglitazar solution is prepared with polyvinylpyrrolidone (solved in a proper solvent) separately. Separately, sugar pellets are coated. Solution of polymethyl methacrylate is prepared and sugar pellets comprising active agents are coated. Pellets are first mixed with crospovidon, colloidal silicon dioxide and then magnesium stearate for a short time. Then, they are filled into capsules.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A pharmaceutical combination comprising vildagliptin or a pharmaceutically acceptable salt thereof in combination with a PPAR dual agonist or a pharmaceutically acceptable salt thereof.

Description

Description
PHARMACEUTICAL COMBINATIONS OF VILDAGLIPTIN AND PPAR AGONISTS Field of Invention
The present invention relates to a pharmaceutical combination comprising vildagliptin or a pharmaceutically acceptable salt thereof in combination with a PPAR dual agonist or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient.
Background of Invention
Vildagliptin is a DPP-IV inhibitor used for type 2 or non-insulin dependent diabetes. It increases the amount of insulin produced by the body. It also decreases the amount of glucagon which is produced by the body. Because of these effects, vildagliptin can help to control blood sugar levels in people with diabetes.
DPP-IV inhibitors work by blocking the action of DPP-IV, an enzyme which destroys the hormone incretin. There are two types of incretin hormones found in the body, called glucagon-like peptide-1 (GLP-1 ) and glucose-dependent insulinotropic peptide (GIP). These hormones are naturally produced by the body in response to food intake. Their function is to help the body produce more insulin only when it is needed and reduce the amount of glucose being produced by the liver when it is not needed. Vildagliptin works by binding to DPP-IV and preventing it from breaking down the GLP-1 and GIP. This increases the levels of these hormones in the body and so increases their effect on controlling blood sugar.
Figure imgf000002_0001
Formula I Its chemical name is (S)-{[(3-hydroxyadamantan-1 -yl)amino]acetyl}pyrrolidine-2-carbonitril and its chemical structure is shown in the Formula I.
Vildagliptin is marketed under the trademark Galvus® in 50 mg dosage forms by NOVARTIS. It is used against diabetes mellitus, particularly in treating type 2 diabetes. Galvus® includes lactose anhydrose, microcrystalline cellulose, sodium starch glycolate and magnesium stearate.
Tablets comprising combinations of vildagliptin are also available in the market in the strength of 50mg/850mg and 50mg/1000mg (vildagliptin/metformin). Eucreas® (vildagliptin and metformin combination) is a dipeptidyl peptidase-4 (DPP-4) inhibitor and biguanide combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. However, there is no combination of vildagliptin and PPAR dual agonists in prior art or in the market for the treatment of cardiovascular disease in patients with type-2 diabetes mellitus.
PPAR agonists are drugs which act upon the peroxisome proliferator-activated receptor. Over the last decade, the members of the peroxisome proliferator-activated receptor (PPAR) subclass have emerged as valuable pharmacological targets whose activation can normalize metabolic dysfunctions and reduce some cardiovascular risk factors associated with type-2 diabetes mellitus.
PPAR (peroxisome proliferator-activated receptor) agonists are divided into five classes PPARa (alpha), PPARy (gamma), PPAR5 (delta), dual acting PPARa/γ (alpha/gamma) and PPAR pan (alpha/delta/gamma) agonists.
PPAR alpha agonists (glitazones) are used for dyslipidemia to increase HDL (High Density Lipoprotein), decrease TG (Triglycerides) without effect on LDL (Low Density Lipoprotein). PPAR gamma agonists (fibrates) are insulin sensitizers for type 2 diabetes. PPAR delta agonists are developed to deal with glucose resulting in insulin resistance and diabetes. PPAR pan (alpha/delta/gamma) agonists are for combined treatment of type 2 diabetes and dyslipidemia. PPAR dual (alpha and gamma) agonists (glitazars) are for combined treatment of type 2 diabetes and dyslipidemia. PPAR alpha agonists are also known as glitazones or thiazolidinediones (TZDs). They comprise pioglitazone, rosiglitazone, ciglitazone, darglitazone, englitazone, lobeglitazone, mitaglitazone, netoglitazone and troglitazone. PPAR gamma agonists (also known as fibrates) comprise bezafibrate, ciprofibrate, clofibrate, gemfibrozil, fenofibrate, simfibrate, lifibrate, pirifibrate, theofibrate, tiafibrate, timofibrate, tocofibrate.
PPAR delta agonists comprise endurobol.
PPAR dual (alpha and gamma) agonists (also known as glitazars) comprise saroglitazar, aloglitazar, chiglitazar, farglitazar (faraglitazar), imiglitazar, muraglitazar, naveglitazar, ragaglitazar, reglitazar, peliglitazar, pemoglitazar, sodelglitazar, tesaglitazar, oxeglitazar, and sipoglitazar.
PPAR dual agonists are the glitazars that combine increased insulin sensitization with lipid control. They bind and activate both the alpha and gamma PPAR isoforms and improvement is achieved both in lipid profiles and insulin sensitization while avoiding dyslipidemia and weight gain.
PPAR dual agonists (glitazars) are ideally suitable drugs in treatment of type 2 diabetic patients who have cardiovascular risk secondary to elevated triglyceride concentration. These molecules do not only target the dyslipidemia but also contribute to improved glycemic control.
Vildagliptin increases plasma GLP-1 concentration and elevate cellular cAMP levels in pancreatic beta-cells leading to potentiate insulin secretion, whereas PPAR agonists dual regulate lipid homeostasis, cellular differentiation, proliferation and the immune response. Therefore, it is anticipated that a combination therapy of vildagliptin and PPAR dual agonists may synergistically represents a novel approach to modify metabolic risk factors associated with adverse cardiovascular outcomes in patients with type 2 diabetes.
Saroglitazar is marketed under the trade name Lipaglyn recommended in strength of 4 mg, developed by the Zydus Cadila. Lipaglyn has been approved for the treatment of Type II diabetes by the Drug Controller General of India in 2013. Lipaglyn is indicated for the treatment of diabetic dyslipidemia and hypertriglyceridemia with Type 2 diabetes mellitus not controlled by statin therapy. In clinical studies, Lipaglyn has demonstrated reduction of triglycerides (TG), low density lipoprotein (LDL) cholesterol, very low density lipoprotein (VLDL) cholesterol, non - high density lipoprotein (non- HDL) cholesterol and an increase in HDL cholesterol. It has also shown favorable glycemic indices by reducing the fasting plasma glucose and glycosylated hemoglobin in diabetic patients. The chemical name of saroglitazar is (2S)-2-ethoxy-3-[4-[2-[2-methyl-5-(4-methylsulfanylphenyl)pyrrol-1 -yl]ethoxy]phenyl] propanoic acid and the chemical structure is shown in Formula II.
Figure imgf000005_0001
Formula II - Saroglitazar Ragaglitazar is a dual peroxisome proliferator-activated receptor (PPAR) alpha and gamma agonist intended to restore insulin sensitivity and ameliorate diabetic dyslipidemia. It is first disclosed in the patent numbered W09919313 in 1997. The chemical name of Ragaglitazar is (2S)-2-ethoxy-3-[4-(2-phenoxazin-10-ylethoxy)phenyl]propanoic acid and the chemical structure is shown in Formula III.
Figure imgf000005_0002
Formula III - Ragaglitazar
Reglitazar is a PPAR dual agonist which is first disclosed in the patent numbered W09518125 in 1993. The chemical name of Reglitazar is 4-[[4-[2-(5-methyl-2-phenyl-1 ,3- oxazol-4-yl)ethoxy]phenyl]methyl]-1 ,2-oxazolidine-3,5-dione and the chemical structure is shown in Formula IV.
Figure imgf000006_0001
Formula IV - Reglitazar
Given these benefits of PPAR agonism, there is a need in the art for a pharmaceutical formulation or a dosage form that is to combine a vildagliptin and a PPAR dual agonist. However, some problems may be occurred while combining these two molecules such as instability and physicochemical and therapeutical incompatibility problems.
In this present invention, a pharmaceutical combination comprising vildagliptin or a pharmaceutically acceptable salt thereof in combination with a PPAR dual agonist or a pharmaceutically acceptable salt thereof has been developed to achieve a stable pharmaceutical combination therapy with a safe and effective release.
Description of the invention
The main embodiment of this present invention is to provide a pharmaceutical combination comprising vildagliptin or a pharmaceutically acceptable salt thereof in combination with a PPAR dual agonist or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient.
In one embodiment, PPAR (peroxisome proliferator-activated receptor) dual agonist in the pharmaceutical combination of this present invention is selected from the group comprising saroglitazar, ragaglitazar, reglitazar, imiglitazar, aloglitazar, chiglitazar, farglitazar (faraglitazar), muraglitazar, naveglitazar, peliglitazar, pemoglitazar, sodelglitazar, tesaglitazar, oxeglitazar, sipoglitazar or pharmaceutically acceptable salt thereof.
According to one embodiment, vildagliptin is present in an amount of between 1 .5 - 90%, preferably 15 - 50% and more preferably 25 - 35% by weight of total formulation.
According to one embodiment, a PPAR dual agonist is present in an amount of between 0.5 - 90.0 %, preferably 1 .0 - 50.0 % and more preferably 10.0 - 45.0 % by weight of total formulation. According to this embodiment, the PPAR dual agonist is preferably saroglitazar or reglitazar or ragaglitazar their acceptable salts thereof. In this embodiment, saroglitazar or a pharmaceutically acceptable salt used in the formulation is saroglitazar magnesium salt.
According to this embodiment, the pharmaceutical combination of this present invention comprises vildagliptin and saroglitazar or a pharmaceutically acceptable salt thereof.
According to another embodiment, the pharmaceutical combination of this present invention comprises vildagliptin and reglitazar or a pharmaceutically acceptable salt thereof.
According to a further embodiment, the pharmaceutical combination of this present invention comprises vildagliptin and ragaglitazar or a pharmaceutically acceptable salt thereof.
According to this embodiment, vildagliptin present in an amount of between 25 mg and 200 mg and the saroglitazar is present in an amount of 0.1 mg and 5 mg. According to this embodiment, vildagliptin present in an amount of between 25 mg and 200 mg and the reglitazar is present in an amount of 0.5 mg and 100 mg.
According to this embodiment, vildagliptin present in an amount of between 25mg and 200 mg and the ragaglitazar is present in an amount of 0.5 and 100 mg.
According to one embodiment, the pharmaceutical combination is in the form of tablets (comprising compressed, coated or uncoated), bilayer tablets, multilayer tablets, orally disintegrating tablets, mini tablets, capsules, pellet, sugar pellet, buccal tablets, sublingual tablets, effervescent compositions, effervescent tablets, immediate release tablets, modified release tablets, film-coated tablets, gastric disintegrating tablets, pills, hard or soft gelatin capsules, oral granules, powders, coated bead systems, granules, microspheres, tablet in tablet or inlay tablets, ion exchange resin systems, sterile solutions or suspensions, steril ocular solutions, aerosols, sprays, drops, ampoules, suppositories, ocular systems, parenteral systems, creams, gels, ointments, dragees, sachets; films, orally administrable films, solutions, solids; elixirs, tinctures, suspensions, syrups, colloidal dispersions, dispersions, emulsions and thereof. In this embodiment, pharmaceutical combination is formulated preferably in the form of tablet or capsule or bilayer tablet comprising vildagliptin or a pharmaceutically acceptable salt and PPAR dual agonist or a pharmaceutically acceptable salt. One embodiment of the present invention is to obtain a stable pharmaceutical combination comprising vildagliptin or a pharmaceutically acceptable salt and a PPAR dual agonist or a pharmaceutically acceptable salt in one dosage form.
While combining more than one molecule in one dosage form is increasing the patients' quality of life, many challenges also occur such as the physicochemical compatibility and the therapeutical compatibility between the two active agents. It is essential to achieve the compatibility between different active agents and/or between active agents and excipients used. Compounds of different classes cannot always be combined into safe and efficacious dosage forms thereby resulting in incompatible drug combinations. Due to chemical interaction between active agents or between active agents and excipients, stability and release problems may occur.
Stability related problems do occur in many active agents, including vildagliptin, under the influence of ambient and physical conditions. Vildagliptin, however, is an active agent that is highly-susceptible to air and humidity. When vildagliptin is exposed to air and humidity, it degrades structurally and develops chemical behavioral changes that may cause undesired release profile or even additional side effects.
Additionally, it has been known that DPP-4 inhibitors with primary or secondary amine group show incompatibilities, degradation problems or extraction problems with excipients. Vildagliptin has also a secondary amine group on its chemical structure. In solid dosage forms, it may react with many excipients or impurities of excipients, although vildagliptin itself is very stable. Especially decomposition which may be caused by reaction (e.g. by acylation, urea formation or Maillard reaction, or the like) of free base type vildagliptin when combined with an incompatible drug molecule, or its impurity and/or a pharmaceutical excipient to form derivatives with the free base type vildagliptin, such as N-acetyl or N-carbamoyl derivatives. Therefore, in this invention, by the use of suitable excipients within these pharmaceutical combinations, protection against oxidation, decomposition and degradation which cause undesired release profile could be achieved. According to this embodiment of the present invention is to obtain a pharmaceutical combination comprising vildagliptin or a pharmaceutically acceptable salt and a PPAR dual agonist or a pharmaceutically acceptable salt which provides the desired release profile. According to one embodiment, pharmaceutical combination of this present invention comprise at least one pharmaceutical excipient selected from the group comprising diluents, disintegrants, binders, glidants, lubricants, super-disintegrants, acidifying agents, alkalizing agents, sweeteners, aromas or mixtures thereof. Suitable diluents are selected from the group comprising dibasic calcium phosphate, mannitol, lactose, microcrystalline cellulose (MCC), spray-dried lactose, sorbitol, sucrose, trehalose, isomalt, starch, calcium phosphate anhydrate, calcium phosphate dihydrate, calcium phosphate trihydrate, tribasic calcium phosphate, calcium carbonate, calcium sulfate, carboxymethyl cellulose calcium, powdered cellulose, cellulose acetate, pregelatinized starch, sodium carbonate, sodium bicarbonate, isomalt, maltodextrine, dextrose, calcium carbonate, sugars, magnesium carbonate, corn starch or mixtures thereof.
In this invention, to achieve the stability of both vildagliptin or a pharmaceutically acceptable salt and PPAR dual agonist or a pharmaceutically acceptable salt, selection of excipients and the ratio of them are very essential. It is surprisingly found that when dibasic calcium phosphate was used as a diluent, stability and desired release profile could be achieved at the same time due to its non-hygroscopic and hydrophobic properties.
According to this embodiment, in this formulation of the present invention dibasic calcium phosphate is used as a diluent.
According to this embodiment, to achieve desired release of both molecules, in this formulation of the present invention dibasic calcium phosphate is used in an amount of % 5.0 - 90.0 by the weight of total formulation.
Suitable disintegrants are selected from the group comprising crospovidon (cross-linked polyvinylpyrrolidone), copovidon, polyvinylpyrrolidone (povidone), croscarmellose sodium, polycarbophil, low-substitue HPC (hydroxylpropyl cellulose), poloxamer, sodium starch glycolate, microcristalline cellulose, starch, alginic acid and alginates, ion-exchange resins, magnesium aluminum silica, sodium dodecyl sulphate, sodium carboxy methyl cellulose, carboxy methyl cellulose calcium, docusate sodium, guar gum, polyacrylin potasium, sodium alginate, sodium glysin carbonate, sodium lauryl sulphate or mixtures thereof.
Suitable binders are selected from the group comprising crospovidon (cross-linked polyvinylpyrrolidone), polyvinylpyrrolidone (povidone), pullulan, polymethacrylate, glyceryl behenate, hydroxypropyl methyl cellulose (HPMC), hydroxypropyl cellulose (HPC), carboxymethyl cellulose (CMC), methyl cellulose (MC), hydroxyethyl cellulose, sodium carboxymethyl cellulose (Na CMC), carboxymethyl cellulose calcium, ethyl cellulose and other cellulose derivatives, polymetacrylates, polyethylene oxide, polyvinyl alcohol, polycarbophil, polyvinyl acetate and their copolymers, gelatin, starch, xanthan gum, guar gum, alginate, carrageen, kollagen, agar, pectin, hyaluronic acid, carbomer, cellulose acetate phthalate, hydroxypropyl starch, hydroxyethyl methyl cellulose, polaxomer, polyethylene glycol (PEG), sugars, glycose syrups, natural gums, tragacanth gum, polyacrylamide, aluminum hydroxide, benthonite, laponite, setostearyl alcohol, polyoxyethylene-alkyl ethers, acacia mucilage, polydextrose or mixtures thereof.
Suitable glidants are selected from the group comprising colloidal silicon dioxide, talc, aluminum silicate, powdered cellulose, calcium phosphate tribasic, hydrophobic colloidal silica, magnesium oxide, magnesium trisilicate, magnesium silicate or mixtures thereof.
Suitable lubricants are selected from the group comprising magnesium stearate, calcium stearate, mineral oil, sodium stearyl fumarate, talc, polyethylene glycol, glyceryl monostearate, glyceryl palmitostearate, sodium lauryl sulphate, magnesium lauryl sulphate, fumaric acid, zinc stearate, stearic acid, hydrogenated natural oils, silica, paraffin or mixtures thereof.
Super-disintegrant is selected from the group comprising calcium silicate, sodium starch glycolate, croscarmellose sodium, carboxymethyl cellulose calcium, sodium carboxymethyl starch, sodium glycine carbonate, sodium lauryl sulphate, soy polysaccharide, alginic acids and algynates, cross-linked alginic acid, polyacrylin potasium, poloxamer. crospovidone, gellan gum, guar gum, xanthan gum, docusate sodium, magnesium alumina, sodium dodecyl sulfate, ion exchange resins or mixtures thereof.
Acidifying agent is selected from the group comprising fumaric acid, tartaric acid, citric acid monohydrate, citric acid anhydrate, adipic acid, ascorbic acid, acetic acid, hydrochloric acid nitric acid, phosphoric acid, nicotinic acid, acetyl salicylic acid, sulfuric acid, acid salts (such as amino acid hydrochlorides, sodium citrates, sodium citrate dihydrate, disodium citrate, disodium dihydrogen citrate, sodium acid phosphate) or mixtures thereof.
Alkalizing agent is selected from the group comprising sodium glycine carbonate, ammonia solution, ammonium carbonate, diethanolamine, diisopropanolamine, potassium hydroxide, potassium bicarbonate, potassium carbonate, calcium carbonate, sodium bicarbonate, sodium borate, sodium carbonate, sodium hydroxide, trolamine or mixtures thereof.
Suitable sweeteners may include but not limited to thaumatin, mogroside, inuline, erythritol, mogroside, acesulfame-K, aspartame, saccharin or its sodium and calcium salts, sodium cyclamate, sucrose, fructose, glucose, sorbitol or mixtures thereof.
Suitable aromas may include but not limited to fruit aromas such as orange, banana, strawberry, cherry, wild cherry, lemon, etc., and other aromas such as cardamom, anis, mint, menthol, vanillin or the mixtures thereof.
Coating may also preferably be used for the protection from the moisture. It can be selected from the group comprising polyvinyl alcohol-polyethylene glycol copolymers (Kollicoat IR), polyvinyl alcohol or copolymers or mixtures thereof (Opadry AMB), polymethylmetacrylate derivatives, Ethylcellulose Dispersions (Surelease), Kerry-HPC, polyethylene glycol, polyvinylprolidone, polyvinylprolidone-vinyl acetate copolymer (PVP-VA) and all kinds of OpadryTM, as well as pigments, dyes, titanium dioxide, iron oxide, talc or polymethylmetacrylate copolymers (Eudragit). In this present invention, to achieve desired pharmaceutical combination with a desired release profile, compatibility and stability, these formulations have been designed, comprising the following: tablet:
a. 1 .5 - 90.0 % by weight of vildagliptin
b. 0.5 - 90.0 % by weight of PPAR dual agonist
c. 0.1 - 60.0 % by weight of disintegrant
d. 0.1 - 30.0 % by weight of binder
e. 2.0 - 90.0 % by weight of diluent
f. 0.1 - 5.0 % by weight of glidant
g- 0.1 - 5.0 % by weight of lubricant
h. preferably, coating bilayer tablet:
a. 1 .5 - 90.0 % by weight of vildagliptin
b. 0.1 - 60.0 % by weight of disintegrant
c. 0.0 - 30.0 % by weight of binder
d. 0.1 - 90.0 % by weight of diluent
e. 0.1 - 5.0 % by weight of glidant
f. 0.1 - 5.0 % by weight of lubricant g- 0.5 - 90.0 % by weight of PPAR dual agonist
h. 0.1 - 60.0 % by weight of disintegrant
i. 0.0 - 30.0 % by weight of binder
]■ 0.0 - 90.0 % by weight of diluent
k. 0.1 - 5.0 % by weight of glidant
1. 0.1 - 5.0 % by weight of lubricant m. preferably, coating
a. 1 .5 - 90.0 % by weight of vildagliptin
b. 0.1 - 60.0 % by weight of disintegrant
c. 0.5 - 40.0 % by weight of pellet
d. 0.1 - 40.0 % by weight of coating
e. 0.5 - 90.0 % by weight of PPAR dual agonist
f. 0.1 - 60.0 % by weight of disintegrant
g. 0.5 - 40.0 % by weight of pellet
h. 0.1 - 40.0 % by weight of coating
Example 1 : tablet ingredients Amount (%) vildagliptin 1 .5 - 90.0 saroglitazar 0.5 - 90.0 polycarbophil 0.5-30.0
dibasic calcium phosphate 5.0-90.0
croscarmellose sodium 0.25-20.0
colloidal silicon dioxide 0.1 - 0.2
magnesium stearate 0.25-2.0
coating 0.2-10.0
The production of the formulation is carried out as follows: vildagliptin, saroglitazar, polycarbophil, croscarmellose sodium and dibasic calcium phosphate are mixed. Colloidal silicon dioxide is added and mixed. Then, magnesium stearate is added therein and mixed for a short time. Tablet compression is performed and tablets are preferably coated.
Example 2: bilaver tablet ingredients Amount (%)
First layer
vildagliptin 1.5-90.0
dibasic calcium phosphate 5.0-90.0
crospovidon 1.0-30.0
colloidal silicon dioxide 0.1 - 0.2
magnesium stearate 0.25-2.0
Second layer
saroglitazar 0.5-90.0
dibasic calcium phosphate 5.0-90.0
crospovidon 1.0-30.0
microcrystalline cellulose 5.0 -90.0
colloidal silicon dioxide 0.1 - 0.2
magnesium stearate 0.25-2.0
coating 0.2-10.0 The production of the formulation is carried out as follows:
First layer: vildagliptin, dibasic calcium phosphate, crospovidon and colloidal silicon dioxide are mixed. Then, magnesium stearate is added and mixed again. The mixture is passed through the roller compactor.
Second layer: saroglitazar, dibasic calcium phosphate, crospovidon, microcrystalline cellulose and colloidal silicon dioxide are mixed. Then, magnesium stearate is added and mixed for a short time. The mixture is passed through the roller compactor.
Granules are sieved and mixed with magnesium stearate. Then, they compressed into bilayer tablets. Tablets are preferably coated.
Example 3: bilaver tablet - hot melt process
Figure imgf000014_0001
The production of the formulation is carried out as follows: vildagliptin, dibasic calcium phosphate, crospovidon and microcrystalline cellulose are mixed. Reglitazar and poloxamer are mixed and passed through the extruder, cooled and sieved. Both phases are mixed with first colloidal silicon dioxide and then magnesium stearate for a short time. Tablet compression is performed. Tablets are preferably coated.
Example 4: capsule
Figure imgf000015_0001
The production of the formulation is carried out as follows: vildagliptin and ragaglitazar solution is prepared with polyvinylpyrrolidone (solved in a proper solvent) separately. Separately, sugar pellets are coated. Solution of polymethyl methacrylate is prepared and sugar pellets comprising active agents are coated. Pellets are first mixed with crospovidon, colloidal silicon dioxide and then magnesium stearate for a short time. Then, they are filled into capsules.

Claims

A pharmaceutical combination comprising vildagliptin or a pharmaceutically acceptable salt thereof in combination with a PPAR dual agonist or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient.
The pharmaceutical combination according to claim 1 , wherein the PPAR dual agonist is selected from the group comprising saroglitazar, ragaglitazar, reglitazar, imiglitazar, aloglitazar, chiglitazar, farglitazar, muraglitazar, naveglitazar, peliglitazar, pemoglitazar, sodelglitazar, tesaglitazar, oxeglitazar, sipoglitazar or a pharmaceutically acceptable salt thereof.
The pharmaceutical combination according to claim 1 , wherein vildagliptin is present in an amount of between 1 .5 - 90%, preferably 15 - 50% and more preferably 25 - 35% by weight of total formulation.
The pharmaceutical combination according to claim 1 , wherein the PPAR dual agonist is present in an amount of between 0.5 - 90.0 %, preferably 1 .0 - 50.0 % and more preferably 10.0 - 45.0 % by weight of total formulation.
The pharmaceutical combination according to claim 1 , wherein the PPAR dual agonist is preferably saroglitazar or reglitazar or ragaglitazar or an acceptable salt thereof.
The pharmaceutical combination according to claim 1 or 5, comprising vildagliptin and saroglitazar or a pharmaceutically acceptable salt thereof.
The pharmaceutical combination according to claim 1 or 5, comprising vildagliptin and reglitazar or a pharmaceutically acceptable salt thereof.
The pharmaceutical combination according to claim 1 or 5, comprising vildagliptin and ragaglitazar or a pharmaceutically acceptable salt thereof.
The pharmaceutical combination according to claim 1 or 6, wherein vildagliptin present in an amount of between 25 mg and 200 mg and the saroglitazar is present in an amount of 0.1 mg and 5 mg.
10. The pharmaceutical combination according to claim 1 or 7, wherein vildagliptin present in an amount of between 25 mg and 200 mg and the reglitazar is present in an amount of between 0.5 mg and 100 mg.
1 1 . The pharmaceutical combination according to claim 1 or 8, wherein vildagliptin present in an amount of between 25mg and 200 mg and the ragaglitazar is present in an amount of 0.5 and 100 mg.
12. The pharmaceutical combination according to any preceding claims, wherein said pharmaceutical combination is in the form of tablets comprising compressed, coated or uncoated tablets, bilayer tablets, multilayer tablets, orally disintegrating tablets, mini tablets, capsules, pellets, sugar pellets, buccal tablets, sublingual tablets, effervescent compositions, effervescent tablets, immediate release tablets, modified release tablets, film-coated tablets, gastric disintegrating tablets, pills, hard or soft gelatin capsules, oral granules, powders, coated bead systems, granules, microspheres, sachets, tablet in tablet or inlay tablets, ion exchange resin systems, sterile solutions or suspensions, steril ocular solutions, aerosols, sprays, drops, ampoules, suppositories, ocular systems, parenteral systems, creams, gels, ointments, dragees, films, orally administrable films, solutions, solids; elixirs, tinctures, suspensions, syrups, colloidal dispersions, dispersions, emulsions and thereof.
13. The pharmaceutical combination according to claim 12, wherein said pharmaceutical combination is formulated preferably in the form of tablet or capsule or bilayer tablet.
14. The pharmaceutical combination according to claim 1 , wherein at least one pharmaceutically acceptable excipient is selected from the group comprising diluents, disintegrants, binders, glidants, lubricants, super-disintegrants, acidifying agents, alkalizing agents, sweeteners, aromas or mixtures thereof.
15. The pharmaceutical combination according to claim 14, wherein the diluents are selected from the group comprising dibasic calcium phosphate, mannitol, lactose, microcrystalline cellulose (MCC), spray-dried lactose, sorbitol, sucrose, trehalose, isomalt, starch, calcium phosphate anhydrate, calcium phosphate dihydrate, calcium phosphate trihydrate, tribasic calcium phosphate, calcium carbonate, calcium sulfate, carboxymethyl cellulose calcium, powdered cellulose, cellulose acetate, pregelatinized starch, lactose monohydrate, sodium carbonate, sodium bicarbonate, isomalt, maltodextrine, dextrose, calcium carbonate, sugars, magnesium carbonate, corn starch or mixtures thereof, preferably dibasic calcium phosphate.
16. The pharmaceutical combination according to claim 15, wherein the dibasic calcium phosphate is present in an amount of between 5.0 - 90.0% by weight of total formulation.
17. The pharmaceutical combination according to any preceding claims comprising; a. 1 .5 - 90.0 % by weight of vildagliptin
b. 0.5 - 90.0 % by weight of PPAR dual agonist
c. 0.1 - 60.0 % by weight of disintegrant
d. 0.1 - 30.0 % by weight of binder
e. 2.0 - 90.0 % by weight of diluent
f. 0.1 - 5.0 % by weight of glidant
g. 0.1 - 5.0 % by weight of lubricant
h. preferably, coating
PCT/EP2015/074939 2014-10-30 2015-10-28 Pharmaceutical combinations of vildagliptin and ppar agonists WO2016066668A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP15797264.7A EP3212185A1 (en) 2014-10-30 2015-10-28 Pharmaceutical combinations of vildagliptin and ppar agonists

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
TR2014/12671 2014-10-30
TR201412671 2014-10-30
TR201413046 2014-11-06
TR2014/13046 2014-11-06

Publications (1)

Publication Number Publication Date
WO2016066668A1 true WO2016066668A1 (en) 2016-05-06

Family

ID=54601735

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2015/074939 WO2016066668A1 (en) 2014-10-30 2015-10-28 Pharmaceutical combinations of vildagliptin and ppar agonists

Country Status (3)

Country Link
EP (1) EP3212185A1 (en)
MA (1) MA40869A (en)
WO (1) WO2016066668A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020165782A1 (en) * 2019-02-13 2020-08-20 Cadila Healthcare Limited Treatment for polycystic ovarian syndrome (pcos)
WO2020183379A1 (en) * 2019-03-11 2020-09-17 Cadila Healthcare Limited Novel salts, crystalline forms and premix of hypolipidemic agent
WO2021262115A1 (en) * 2020-06-25 2021-12-30 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A stable combination of vildagliptin and metformin hci

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995018125A1 (en) 1993-12-27 1995-07-06 Japan Tobacco Inc. Isoxazolidinedione derivative and use thereof
WO1999019313A1 (en) 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
WO2004048338A1 (en) * 2002-11-26 2004-06-10 Shenzhen Chipscreen Biosciences Ltd. Noncyclic 1,3-dicarbonyl compounds as dual ppar agonists with potent antihyperglycemic and antihyperlipidemic activity
US20060270722A1 (en) * 2005-05-31 2006-11-30 Thornberry Nancy A Combination of a dipeptidyl peptidase-IV inhibitor and a dual PPAR agonist for the treatment of diabetes and obesity
WO2007120936A2 (en) * 2006-01-06 2007-10-25 Novartis Ag Use.of vildagliptin for the treatment of diabetes
EP2468256A1 (en) * 2010-12-21 2012-06-27 Sanovel Ilac Sanayi ve Ticaret A.S. Combinations of vildagliptin and glimepiride
EP2468268A1 (en) * 2010-12-21 2012-06-27 Sanovel Ilac Sanayi ve Ticaret A.S. Combination composition of vildagliptin and gliclazide
WO2013036213A1 (en) * 2011-09-07 2013-03-14 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dpp-iv inhibitor formulations
WO2014195967A2 (en) * 2013-05-30 2014-12-11 Cadila Healthcare Limited A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995018125A1 (en) 1993-12-27 1995-07-06 Japan Tobacco Inc. Isoxazolidinedione derivative and use thereof
WO1999019313A1 (en) 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
WO2004048338A1 (en) * 2002-11-26 2004-06-10 Shenzhen Chipscreen Biosciences Ltd. Noncyclic 1,3-dicarbonyl compounds as dual ppar agonists with potent antihyperglycemic and antihyperlipidemic activity
US20060270722A1 (en) * 2005-05-31 2006-11-30 Thornberry Nancy A Combination of a dipeptidyl peptidase-IV inhibitor and a dual PPAR agonist for the treatment of diabetes and obesity
WO2007120936A2 (en) * 2006-01-06 2007-10-25 Novartis Ag Use.of vildagliptin for the treatment of diabetes
EP2468256A1 (en) * 2010-12-21 2012-06-27 Sanovel Ilac Sanayi ve Ticaret A.S. Combinations of vildagliptin and glimepiride
EP2468268A1 (en) * 2010-12-21 2012-06-27 Sanovel Ilac Sanayi ve Ticaret A.S. Combination composition of vildagliptin and gliclazide
WO2013036213A1 (en) * 2011-09-07 2013-03-14 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dpp-iv inhibitor formulations
WO2014195967A2 (en) * 2013-05-30 2014-12-11 Cadila Healthcare Limited A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020165782A1 (en) * 2019-02-13 2020-08-20 Cadila Healthcare Limited Treatment for polycystic ovarian syndrome (pcos)
WO2020183379A1 (en) * 2019-03-11 2020-09-17 Cadila Healthcare Limited Novel salts, crystalline forms and premix of hypolipidemic agent
WO2021262115A1 (en) * 2020-06-25 2021-12-30 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A stable combination of vildagliptin and metformin hci

Also Published As

Publication number Publication date
EP3212185A1 (en) 2017-09-06
MA40869A (en) 2017-09-05

Similar Documents

Publication Publication Date Title
JP7565589B2 (en) Pharmaceutical combinations, compositions, and formulations containing glucokinase activators and DPP-IV inhibitors, and methods of preparation and use thereof - Patents.com
EP3212185A1 (en) Pharmaceutical combinations of vildagliptin and ppar agonists
US9795592B2 (en) Pharmaceutical formulations of vildagliptin
EP3976014A1 (en) A combination comprising alogliptin and metformin
EP2468256B1 (en) Combinations of vildagliptin and glimepiride
WO2016066666A1 (en) Pharmaceutical combinations of sitagliptin and ppar agonists
US20190070120A1 (en) Pharmaceutical Composition Comprising Canagliflozin, Process of Preparation and Use Thereof
EP4171533A1 (en) A film coated tablet comprising vildagliptin and metformin hci
TR2022013357A2 (en) ORAL THERAPEUTIC FORMULATIONS
TR202012601A2 (en) TABLET FORMULATION CONTAINING CYTAGLIPTIN AND METFORMIN
TR2022013356A2 (en) ORAL THERAPEUTIC FORMULATIONS
WO2021262115A1 (en) A stable combination of vildagliptin and metformin hci
TR201605929A1 (en) THERAPEUTIC FORMULATIONS FOR THE TREATMENT OF DIABETES
TW201114419A (en) Pharmaceutical composition for Parkinson's disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15797264

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2015797264

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载